Immunoglobulin production regulation

Immunoglobulin production regulation refers to the complex physiological process that controls the development of B-lymphocytes into antibody-secreting plasma cells and the maintenance of humoral immunity. This process is not a single molecular target but rather a network of interactions involving cytokines like BAFF (B-cell activating factor) and APRIL, cell-surface receptors such as CD20 and CD40, and intracellular signaling pathways (Nature Reviews Immunology, 2005). In healthy individuals, this regulation ensures appropriate responses to pathogens while preventing the production of autoantibodies. Dysregulation of this process is a hallmark of various diseases, including systemic lupus erythematosus (SLE), where overactive B-cells produce harmful autoantibodies, and primary immunodeficiencies, where antibody production is impaired (Journal of Allergy and Clinical Immunology, 2013). Therapeutic strategies to modulate this process include B-cell depletion using monoclonal antibodies like Rituximab or the inhibition of survival signals with agents like Belimumab (Lancet, 2011). Because this term describes a broad biological pathway rather than a specific protein or receptor, it is classified as a biological process rather than a discrete therapeutic target.

Other names

Regulation of humoral immune responseAntibody production regulationB-cell differentiation regulationControl of immunoglobulin secretion

Drugs modulate this process by targeting specific B-cell surface markers, cytokines, or intracellular kinases to inhibit the differentiation, survival, and antibody-secreting capacity of B-lymphocytes and plasma cells.